

March 31, 1987

Robert Martz, M.D.
Group Director- CNS Diseases
Du Pont - Medical Products Department
Wilmington, Delaware 19898

Dear Dr. Martz,

I thought that I had sent a copy of our response to the FDA regarding IND 21,821 to you, but I may not have.

In response to a request from the FDA in June, 1986, I noted our failure to affect the EEG or the behavior of our psychiatric patients during the course of convulsive therapy by doses of naloxone up to 20 mg. As our findings were consistent with other reports, we discontinued the study. We have not published the results of our experience. The remaining supplies of naloxone were outdated and destroyed.

Copies of our formal notification of the FDA and their reply are enclosed.

Thank you very much for your cooperation and assistance in the study.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry